CHAM
TVRD

Clear Harbor Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Clear Harbor Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-14
Closed -$6.36K – 754
2020
Q3 		$6.36K Buy
+14
New +$8.13K ﹤0.01% 642
2020
Q1 		– Sell
-14
Closed -$8.05K – 721
2019
Q4 		$8.05K Buy
+14
New +$9.82K ﹤0.01% 628

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Clear Harbor Asset Management's TVRD Position: Q4 2020 in Review

Clear Harbor Asset Management sold out of Tvardi Therapeutics (TVRD) in Q4 2020, closing a stake of 14 shares — an estimated $6.36K sold.

Clear Harbor Asset Management first reported a position in TVRD in Q4 2019 and held it in 2 quarters. The position peaked at $8.05K in Q4 2019. 155 funds tracked by Wall St. Rank hold TVRD as of Q4 2020.

  • Clear Harbor Asset Management reported no remaining Tvardi Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Clear Harbor Asset Management sold 14 Tvardi Therapeutics shares in Q4 2020, an estimated $6.36K.
  • Clear Harbor Asset Management first reported a position in Tvardi Therapeutics in Q4 2019 and held it in 2 quarters.
  • Clear Harbor Asset Management's Tvardi Therapeutics position peaked at $8.05K in Q4 2019.
  • 155 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2020.

Based on Clear Harbor Asset Management's 13F filing for Q4 2020, filed 4 Feb 2021.